Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Suzuki K, Yasui Y, Tsuchiya K, Matsumoto H, Yamazaki Y, Uchihara N, Tanaka Y, Miyamoto H, Yamada-Shimizu M, Keitoku T, Okada R, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Nakanishi H, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N.
Suzuki K, et al. Among authors: higuchi m.
J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532. Online ahead of print.
J Gastroenterol Hepatol. 2024.
PMID: 38494668